Patents Assigned to Genentech
  • Nouvelles compositions et methods de traitement du psoriasis
    Publication number: 20070042945
    Abstract: The present invention relates to compositions and methods useful for the diagnosis and treatment of psoriasis.
    Type: Application
    Filed: September 25, 2003
    Publication date: February 22, 2007
    Applicant: Genentech, Inc.
    Inventors: Sarah Bodary, Hilary Clark, Janet Jackman, Jill Schoenfeld, P Williams, William Wood, Thomas Wu
  • Method for treating tumors using anti-osteopontin antibodies
    Publication number: 20070041983
    Abstract: The present invention is directed to compositions of matter useful for the treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 22, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Robert Pitti, Thomas Wu, Zemin Zhang
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20070036753
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • Serine Protease Inhibitors
    Publication number: 20070037813
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean Artis, Michael Dina, John Flygare, Richard Goldsmith, Regina Munroe, Alan Olivero, Richard Pastor, Thomas Rawson, Kirk Robarge, Daniel Sutherlin, Kenneth Weese, Aihe Zhou, Yan Zhu
  • VEGF-RELATED PROTEIN
    Publication number: 20070036813
    Abstract: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.
    Type: Application
    Filed: June 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: James Lee, William Wood
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20070036755
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mess, William Novotny
  • ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa
    Publication number: 20070037814
    Abstract: Compounds having the general formula I are useful for inhibiting serine protease enzymes, such as Tissue Factor VIIa, factor Xa, thrombin and kallikrein and have improved permeability properties. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Thomas Rawson, Lewis Gazzard
  • Expression Vectors and Methods
    Publication number: 20070037254
    Abstract: Vectors and methods for efficient isolation of recombinant cells expressing high levels of a desired protein are provided. The vectors comprise an amplifiable selectable gene, a fluorescent protein gene, and a gene encoding a desired product in a manner that optimizes transcriptional and translational linkage.
    Type: Application
    Filed: September 25, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Vanessa Chisholm, Craig Crowley, Lynne Krummen, Yu-Ju Meng
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20070036754
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • Apo-2DcR
    Publication number: 20070037191
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: June 27, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Kevin Baker, Anan Chuntharapai, Austin Gurney, Kyung Kim, William Wood
  • Altered polypeptides with increased half-life
    Publication number: 20070031922
    Abstract: Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.
    Type: Application
    Filed: November 17, 2005
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Leonard Presta, Bradley Snedecor
  • Treatment of Disorders
    Publication number: 20070031331
    Abstract: The present invention concerns treatment of polychondritis or mononeuritis multiplex in a mammal with an effective amount of an antibody that binds to CD20, optionally also with another agent that treats such disorders in an effective amount.
    Type: Application
    Filed: September 26, 2006
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Paul Brunetta, Kathryn Sewell
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20070031413
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20070031901
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: July 14, 2006
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Audrey Goddard, Paul Godowski, Austin Gurney, Paul Polakis, P. Williams, William Wood, Thomas Wu, Zemin Zhang
  • Process for Protein Extraction
    Publication number: 20070031930
    Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 8, 2007
    Applicant: GENENTECH, INC.
    Inventor: Richard Gehant
  • Compositions and methods for modulating vascular development
    Publication number: 20070031437
    Abstract: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
    Type: Application
    Filed: October 12, 2006
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Ellen Filvaroff, Weilan Ye, Leon Parker, Jo-Anne Hongo, Maike Schmidt
  • Polypeptides Homologous To VEGF and BMP1
    Publication number: 20070031929
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia Kuo
  • Stra6 polypeptides
    Patent number: 7173115
    Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: February 6, 2007
    Assignee: Genentech, Inc.
    Inventors: Diane Pennica, Victoria Smith, William I. Wood
  • Human growth hormone aqueous formulation
    Publication number: 20070027083
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Barbara O'Connor, James Oeswein
  • Human tPA production using vectors coding for DHFR protein
    Patent number: H2181
    Abstract: A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild-type DHFR with methotrexate.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: February 6, 2007
    Assignee: Genentech, Inc.
    Inventors: Arthur D. Levinson, Diane Pennica, William J. Kohr, Gordon A. Vehar, David V. Goeddel, Elizabeth M. Yelverton, Christian C. Simonsen